4Brauers A,Buettner RJakse G. Second resection and progno-sis of primary high risk superficial bladder cancer: Is cystecto-my often too early [J]. J Urol,2001,165(3) :808-810. 被引量：1
5Divrik RT* Sahin AF, Yildirim U,et al. Impact of routinesecond transurethral resection on the long-term outcomeof patients with newly diagnosed pTi urothelial carcinomawith respect to recurrence,progression rate, and disease-specific survival: a prospective randomized clinical trial[J]. Eur Urol,2010,58(2) :185-190. 被引量：1
6Zurkirchen MA, Sulser T? Gaspert A, et al. Second tran-surethral resection of superficial transitional cell carcino-ma of the bladder: A must even for experienced urologists[J], Urol Int,2004,72(2) :99~102. 被引量：1
7Schips L, Augustin H? Zigeuner RE, et al. Is repeatedtransurethral resection justified in patients with newly di-agnosed superficial bladder cancer[J]. Urology, 2002, 59(2):220-223. 被引量：1
8Grimm MO*Steinhoff C,Simon X, et al. Effect of routinerepeat transurethral resection for superficial bladder canc-er: A long-term observational study [J], J Urol,2003,170(2 Pt l):433-437. 被引量：1
9Yucel M,Hatipoglu NK, Atakanli C,et al. Is repeat tran-surethral resection effective and necessary in patients withTi bladder carcinoma[J]. Urol Int,2010,85(3) :276-280. 被引量：1
10Schulze M,Stotz N? Rassweiler J. Retrospective analysisof transurethral resection,second-look resection, andlong-term chemo-metaphylaxis for superficial bladdercancer: indications and efficacy of a differentiated ap*proach [J]. J Endourol,2007,21(12) : 1533-1541. 被引量：1
同被引文献35
1Chen G,He Y,Wu X,et al. In vitro and in vivo studies of pirarubicin-loaded SWNT for the treatment of bladder cancer[J]. Braz J Med Biol Res,2012,45(8) :771-776. 被引量：1
2Colombo R, Rocchini L, Suardi N, et al. Neoadjuvant short- term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-in- vasive bladder cancer., preliminary results of a randomised phase 2 study[J]. Eur Urol, 2012,62 (5) : 797-802. 被引量：1
3Lamm D, Persad' R, Brausi M, et al. Defining Progression in Nonmuscle Invasive Bladder Cancer.. It is Time for a New, Standard Definition[J]. J Urol, 2013,191 ( 1 ): 20-27. 被引量：1
4Maffezzini M,Campodonico F, Manuputty EE, et al. Sys- temic absorption and pharmacokinetics of single-dose ear- ly intravesical mitomycin C after transurethral resection of non-muscle-invasive bladder cancer[J]. Urology, 2013,82(2):400-404. 被引量：1
5Barocas DA, Liu A, Burks FN, et al. Practice based collabora- tion to improve the use of immediate intravesical therapy after resection of nonmusele invasive bladder cancer[J]. J Urol, 2013,190(6) :2011-2016. 被引量：1
6Gilpinar O, Halilioglu AH ,G6ke MI, et al. The value of perioperative mitomycin C instillation in improving subse- quent bacillus calmette-guerin instillation efficacy in inter- mediate and high-risk patients with non-muscle invasive bladder cancer: a prospective randomized study[J-]. Int Braz J Urol,2012,38(4) :474-479. 被引量：1
7Ersoy H,Yaytokgil M, Karakoyunlu AN, et al. Single early instillation of mitomyein C and urinary alkalinization in low- risk non-muscle-invasive bladder cancer: a preliminary study [J]. Drug Des Devel Ther,2013,7(8) :1-6. 被引量：1
8Solsona E, Climent MA, Iborra I, et al. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy [J]. European Urol, 2009,55 ( 4 ) : 911- 919. 被引量：1
